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INTRODUCTION
Hearing loss (HL) is one of the most
common sensory disorders, affecting 2–3
in 1,000 newborns. Mutations in the gap
junction β2 (GJB2) gene encoding the
connexin26 (CX26) protein, are responsi-
ble for approximately 50% of autosomal
recessive nonsyndromic HL in many
populations (1,2). To date, more than 150
different variants have been reported in
GJB2 gene (3; http://davinci.crg.es/
 deafness/) and the spectrum and preva-
lence of the mutations and polymor-
phisms in GJB2 gene vary significantly
among different ethnic groups.
The most frequent pathogenic muta-
tions, c.35delG and c.167delT, account for
70% and 40% of GJB2-related HL in Cau-
casians and Ashkenazi Jews, respectively
(4–7). In contrast, East Asian HL patients
rarely display these mutations, but
 another single base pair deletion,
c.235delC, is present in 7% to 12% of this
group (8,9). Besides these mutations,
p.V27I, p.M34T, p.V37I and p.E114G are re-
ported most frequently in these popula-
tions, but the pathogenicity of these vari-
ants remains controversial (10–12). The
p.M34T variant first was reported as a
pathogenic mutation with a dominant ef-
fect, but this finding was questioned sub-
sequently and the p.M34T was suggested
to be a recessive mutation (13,14). The
p.V37I was described originally as a non-
pathogenic polymorphism, but recently
this variant was proposed to be patho-
genic and associated with mild HL (15,16).
Recent biochemical, electrophysiological
and genetic studies of p.M34T and p.V37I
supported these suggestions (17,18).
The p.V27I and p.E114G variants are
very common, with allele frequencies of
28.3% and 18.3%, respectively, in the East
Asian population (19–21). The p.V27I
variant has been found alone or together
with the p.E114G variant in East Asian
individuals. In contrast, the p.E114G vari-
ant has been found together with the
p.V27I variant in most cases, and these
variants generally occur in cis configura-
tion (22). Each of the p.V27I and p.E114G
variants have been considered benign
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polymorphisms, but when present to-
gether in cis configuration, homozygous
p.V27I/p.E114G has been suggested to
cause HL (23). However, in other studies,
p.V27I/p.E114G variants have been con-
sidered benign polymorphisms, because
p.V27I/p.E114G homozygous genotypes
have been reported in unaffected indi-
viduals (21,24). To resolve these discrep-
ancies, we have investigated the patho-
genicity of different haplotypes of the
p.V27I and p.E114G variants using
in vitro approaches, and assessed the
possible genotype-to-phenotype correla-
tion of these variants with HL in the
 Korean population.
MATERIALS AND METHODS
Subjects
A total of 273 subjects with nonsyn-
dromic HL were recruited from the De-
partment of Otolaryngology, Kyungpook
National University Hospital and Soree
Ear clinic. No evidence of any other clini-
cal symptoms was found, and environ-
mental causes of HL such as ototoxic
drugs and infectious diseases were ex-
cluded by interviews. One hundred
thirty-nine unrelated Koreans with nor-
mal hearing were collected for use as con-
trols. Hearing sensitivity was assessed by
pure tone audiogram (PTA) in a sound-
proof room using a diagnostic audiome-
ter. All participants provided written in-
formed consent according to the protocol
approved by the Ethics Committee.
Molecular Analyses
Genomic DNA of subjects was ex-
tracted from peripheral blood using the
FlexiGene DNA extract kit (QIAGEN,
Hilden, Germany). The GJB2 gene (Gen-
Bank Accession No. NM_004004.5) cod-
ing region was amplified by polymerase
chain reaction (PCR) using the following
primers: forward, 5′-TCT TTT CCA GAG
CAA ACC GC-3′; reverse, 5′-GGG CAA
TGC GTT AAA CTG GC-3′. The PCR
conditions consisted of an initial denatu-
ration step at 95°C for 2 min followed by
35 cycles of denaturation (30 sec at 95°C);
annealing (30 sec at 57°C, depending on
the primers); extension (1 min at 72°C)
and a final extension step at 72°C for
10 min. An ABI 3130XL genetic analyzer
(Applied Biosystems, Foster City, CA,
USA) was used for direct sequencing,
and data was analyzed by using ABI se-
quencing Analysis (v.5.0) and LASER-
GENE-SeqMan software. The samples
were also tested for the presence of mu-
tations in the coding region of GJB3,
GJB4 and GJB6 gene by the method pre-
viously reported by Yang et al. (25).
Construction of CX26 Variants and
Transfection of HEK 293 Cells
The single coding region of human
CX26 was amplified by PCR from ge-
nomic DNA of normal hearing subject
was subcloned into the pEGFP-N1 and
pmCherry-N1 vectors (Clontech Inc,
Mountain View, CA, USA) to create
CX26-EGFP and CX26-mCherry fusion
proteins. The p.V27I and p.E114G variants
in CX26 were created with the
QuikChange site-directed mutagenesis
kit (Stratagene Inc., La Jolla, CA, USA).
Flowing forward and reverse primer con-
taining the CX26 point mutation (mu-
tated bases underlined) were synthe-
sized: p.V27I F, 5′-GAA AGA TCT GGC
TCA CCA TCC TCT TCA TTT TTC GC-3′;
R, 5′-GCG AAA AAT GAA GAG GAT
GGT GAG CCA GAT CTT TC-3′; p.E114G
F, 5′-GGA GAT AAA GAG TGG ATT
TAA GGA CAT CG-3′; R, 5′-CGA TGT
CCT TAA ATC CAC TCT TTA TCT CC-3′.
The correct introduction of intended mu-
tations and the absence of unintended
additional mutations in the CX26–p.V27I
and CX26–p.E114G vector sequences were
confirmed by DNA  sequencing.
The human embryonic kidney HEK293
cell line, which is used widely for gap
junction (GJ) studies because of its lack of
endogenous expression of connexins, was
obtained from the Korean Cell Line Bank
(Seoul, Korea). The cells were detached,
seeded onto glass coverslips, placed in a
Figure 1. Schematic representation of the GJB2 gene and the four amino acid haplo-
types of p.V27I and p.E114G. (A) The boxes represent the two numbered exons, and pro-
tein coding region are marked in gray. The p.V27I and p.E114G are marked with an
arrow; the first line gives the amino acid substitution, the second line is the position and
base substitution starting from the start codon, and the third line is the SNP name 
(rs-number) from NCBI. (B) The amino acid haplotypes of p.V27I and p.E114G are shown;
the circles indicate wild-type amino acid; and the asterisks indicate amino acid substitu-
tion in the positions.
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35-mm Petri dish, and cultured to 80%
confluence 1 d prior to transfection. The
cells were transfected using the Fugene
HD transfection kit (Roche Diagnostics,
Indianapolis, IN, USA) following the
manufacturer’s instructions.
Assays for Measuring Biochemical
Coupling, Ionic Coupling and
Hemichannel Permeability
GJ biochemical coupling was measured
with the single cell dye transfer assay. For
dye transfer assays, one of the two cells
with GJ was injected by microelectrode
filled with a 1% Lucifer Yellow (LY, mo-
lecular weight 457; charge 2–) solution in
intracellular solution (KCl 120 mmol/L,
MgCl2 1 mmol/L, HEPES 10 mmol/L;
pH 7.4 with NaOH). The LY transfer was
recorded 30 s to 3 min after injection
through an electrophoresis method based
on the technique described Haas et al.
(26). Ionic coupling assay was performed
as described previously (26).
The hemichannel assay used Propid-
ium Iodide (PI, molecular weight 650;
charge + 2, Invitrogen) for measurement
of the connexon unitary gating properties
with a dye loading assay. Cells were incu-
bated for 40 min at room temperature in
PI solution prepared in HBSS containing
10 mmol/L EGTA, 1 mmol/L MgCl2, and
0.15 mmol/L PI. The hemichannel assay
was performed using cells transfected
with different vectors plus the pEGFP
vector. Data are expressed as mean and
standard deviation. The data were tested
for significance by using one-way analy-
sis of variance (ANOVA), and only re-
sults with P values of < 0.05 were consid-
ered statistically significant.
Statistical Tests
The SHEsis program (http://analysis.
bio-x.cn/) was used to calculate and esti-
mate allele frequencies, genotype fre-
quencies, haplotype frequencies, and
linkage disequilibrium in controls and
patients. The Statistical Package for the
Social Sciences (SPSS for Windows, ver-
sion 12.0K, SPSS Inc., Chicago, IL, USA)
was used for analysis of the hemichannel
assay data.
All supplementary materials are available
online at www.molmed.org.
RESULTS
We performed in vitro functional analy-
ses and population study for p.V27I and
p.E114G variants to clarify the possible
roles of these variants in HL. This study
examined different combinations of alle-
les of p.V27I (substitution of valine for
isoleucine in codon 27, c.79G>A) and
p.E114G (substitution of glutamic acid for
glycine in codon 114, c.341A>G). These
two alleles at two different sites can com-
prise four amino acid haplotypes, VE
(wild type), I*E (p.V27I variant only), VG*
(p.E114G variant only), and I*G* (both
variants), as shown in Figure 1.
Protein Localization, Biochemical and
Ionic Coupling Test, and Hemichannel
Permeability Test
To examine to which degree haplotypes
affected the level of protein expression
and their cellular localization, the four
vectors with different amino acid haplo-
types were transfected transiently in
HEK293 cells (Figure 2). The VE form of
CX26 was localized at the membrane of
HEK 293 cells and forms GJs as seen by
the characteristic plaques between two ad-
jacent cells (Figure 2A, arrow). Similarly,
the I*E, VG*, and I*G* were expressed at
the membrane region and  retained the
ability to form normal- appearing GJ
plaques (Figure 2B–D, arrows).
To assess the biochemical permeability
of the different haplotype GJ channels, we
examined the cell-to-cell transfer of the
impermeant dye Lucifer Yellow (LY),
which was loaded into one of the cells
forming the GJs with a patch pipette (see
Figure 2). Dye transfer rate was evaluated
by observing the amount of dye trans-
ferred into the other cells and categorized
into three groups; fast transfer (trans-
ferred within 1 min), slow transfer (trans-
ferred between 1 and 2 min), and no
transfer. The p.D46E variant of CX26, a
well known causative mutation in HL,
was used as a negative control (28). This
variant displayed highly defective inter-
cellular dye transfer (Table 1). The cells
transfected with the VE type showed a
high efficiency of LY transfer through GJ
channel, 88.9% of the cells examined
Figure 2. Lucifer Yellow (LY) permeability by GJ of four haplotypes. Arrows indicate 
the presence of GJs shown by pmCherry and pEGFP at the cell membrane bordering 
the two cells. Intercellular coupling was present between cells expressing VE (CX26-
WT-mCherry) (A), I*E (CX26-p.V27I-mCherry) (B), VE and VG* (CX26-WT-EGFP + CX26-
p.E114G-mCherry) (E), and VE and I*G* (CX26-WT-EGFP + CX26-p.V27I/p.E114G-
mCherry) (F). Cell transfected with VG* (CX26-p.E114G-mCherry) (C) and I*G* (CX26-
p.V27I/p.E114G-mCherry) (D) were uncoupled. * Marks the injected cells in the cell pair
tested. These results are monitored 2 min after the injection.
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showed fast transfer (Table 1). The LY
transfer rate of the I*E type was similar to
that of VE type, showing fast transfer in
88.5% of the cells examined. In contrast,
the LY transfer through GJ channels com-
posed of VG* and I*G* types was either
delayed markedly or failed, accounting
for 61.3% (n = 27/44) in the VG* type and
55.4% (n = 31/56) in the I*G* type, respec-
tively. When the assay was carried out
with the cells cotransfected with VE and
VG* or VE and I*G*, the LY transfer was
comparable to that of VE alone (Table 1).
These findings indicate that VG* and I*G*
type GJs display a moderate deficit in GJ-
mediated biochemical coupling on their
own, but in combination with the VE
form in hybrid GJs, they have no signifi-
cant effect. We also tested the ability to
transfer Ca2+ ions intercellularly across the
GJs in four haplotypes and showed a con-
sistent result with biochemical assay (Sup-
plementary Figure 1).
For hemichannel studies, we bathed
cells in normal HBSS which contained
1.2 mmol/L [Ca2+]o, which is known to
keep VE type hemichannel in the closed
state (29). It is also known that Cx
hemichannels are opened by lowering
the extracellular Ca2+ concentration or by
omitting Ca2+ altogether (30). For our
hemichannel functional studies, we used
Ca2+-free HBSS containing 0.15 mmol/L
PI dye. In most of the cells transfected
with VE or I*E types, the entry of the PI
dye through hemichannels was opened
by free calcium (92.3%, n = 1290 and
90.0%, n = 1079, respectively) (Figure 3A,
Supplemental Figure 2A, B). In contrast,
low percentages of the cells transfected
with VG* or I*G* (12.4%, n = 889 and
34.5%, n = 997, respectively) were loaded
with the PI dye (see Figure 3A and Sup-
plemental Figure 2C, D).
We then cotransfected the VE with one
of the I*E, VG* or I*G* types, and exam-
ined the effect on the PI dye transfer (Fig-
ure 3B and Supplemental Figure 2E–G).
Cotransfection of VE/I*E (93.7%)
showed similar PI loading efficiency to
that of VE (92.3%) or I*E (90.0%) alone.
However, cotransfection of VE/VG*
(43.0%) or VE/I*G* (62.1%) displayed
lower PI loading efficiencies compared
with that of VE alone, but higher effi-
ciencies compared with those of VG*
(12.4%) or I*G* (34.5%) alone. Interest-
ingly, the PI loaded through hemichannel
of I*G* type was more than that loaded
through cells transfected with the VG*
type (VG* versus I*G*), and a similar
pattern was observed when cells were
cotransfected with VE (VE/VG* versus
VE/I*G*). We also tested hemichannel
activities in cells expressing I*E types to-
gether with VG* or I*G* types (Figure 3B
and Supplemental Figure 2H, I). The
I*E/VG* type displayed a greater per-
centage of cells with PI dye loading than
VE/VG* type (63.4% and 43.0%, P <
0.05), but no significant difference with
I*E/I*G* type (63.4% and 65.9% respec-
tively). This result suggests that iso -
leucine residue of p.V27I exerts a much
milder effect on hemichannel function
than valine residue of p.V27I in coexis-
tence with glutamic acid of p.E114G.
These results suggest that the VG*
type greatly reduces the hemichannel ac-
tivity, but when complexed with the VE
or I*E types, their hemichannel perme-
abilities were improved, resulting in
higher PI loading efficiencies (P < 0.05,
one-way ANOVA test).
Population Study
We evaluated the presence of two
 variants of the GJB2 gene (GenBank
 Accession No. NM_004004.5), p.V27I
(rs2274084) and p.E114G (rs2274083), in
273 Korean nonsyndromic HL patients
and 139 normal hearing controls. Pa-
tients carrying any other mutations in
the GJB2, GJB3, GJB4 and GJB6 genes
were excluded by sequencing analysis.
Table 2 shows allele and genotype fre-
quency distributions of each variant. The
Table 1. Percentage of the LY dye transfer through GJ channels.
Dye transfer (%)
Type Fast transfer Slow transfer No transfer (%)
VE 24 (88.9) 1 (3.7) 2 (7.4)
p.D46E 2 (7.4) 5 (18.5) 20 (74.1)
I*E 23 (88.5) 2 (7.7) 1 (3.8)
VG* 17 (38.6) 21 (47.7) 6 (13.6)
I*G* 25 (44.6) 21 (37.5) 10 (17.9)
VE/VG* 12 (92.3) 1 (7.7) 0 (0.0)
VE/I*G* 15 (93.8) 1 (6.3) 0 (0.0)
Figure 3. Percentage of transfected HEK293 cells loaded with PI through hemichannels.
Percentage of transfected cells with VE, I*E, VG*, and I*G* types (A) and cotransfection
of I*E, VG*, and I*G* with the VE and I*E, respectively (B). Each bar represents the mean
(± SEM). In the image, the asterisk (*) indicates statistically different to hemichannel
loaded compared to VE type; the number sign (#), statistically different in between
VE/VG* versus VE/I*G* and VE/VG* versus I*E/VG*.
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distributions of genotypes and alleles of
p.V27I and p.E114G were all in Hardy-
Weinberg equilibrium in both patients
and controls. These variants displayed no
significant difference in frequencies of
both alleles (P = 0.501 and P = 0.331) and
genotypes (P = 0.508 and P = 0.330) be-
tween patients and controls. To evaluate
the extent of linkage disequilibrium (LD),
D′ values between p.V27I and p.E114G
were calculated. The D′ value between
these two variants was 0.966, demonstrat-
ing that there is strong linkage disequilib-
rium between them. No significant differ-
ence in haplotype frequencies existed
between patients and controls (Table 3).
DISCUSSION
Mutations in the GJB2 gene are the
major cause of nonsyndromic HL in
many populations (31–33). The p.V27I
and p.E114G variants in GJB2, which
occur frequently in East Asian popula-
tions, have been reported as either poly-
morphisms or mutations (10,23,34,35). In
this study, using in vitro approaches and
a population study, we assessed the path-
ogenicities of the p.V27I and p.E114G
variants in channel function and HL.
The biochemical permeability con-
ferred by I*E type channel was similar to
that of wild type (VE), but CX26 carrying
the VG* or I*G* haplotypes showed
delay or failure of the transfer of dye.
However, the VG* and I*G* forms of
CX26 in combination with the VE or I*E
forms in hybrid GJs did not affect GJ-
 mediated biochemical coupling (see Fig-
ure 2, Table 1). In our hemichannel study,
there was no significant difference be-
tween VE, I*E and VE/I*E, while VG*,
I*G*, VE/VG*, VE/I*G*, I*E/VG* and
I*E/I*G* all displayed a significant dif-
ference in dye transfer compared with
that mediated by the VE type. In all
types, the hemichannels composed of
only VG* type had the most defective
hemichannel activity, and the I*G* type
displayed the next one (Figure 3 and
Supplemental Figure 1). Interestingly, the
hemichannels composed of p.E114G with
p.V27I have milder effect than that
hemichannel composed of p.E114G with
p.V27V (I*G* versus VG*, I*E/VG* ver-
sus VE/VG*). These results suggest that
p.V27I may be capable of compensating
for the loss of hemichannel activity. The
results of our in vitro cell-based assays
indicate that the VG* and I*G* haplo-
types of GJB2 may play a role as patho-
genic variants in hereditary hearing
 impairment.
However, in our study of the hearing
impaired Korean population, we did not
observe a significant difference in the fre-
quencies of these four variant haplotypes
between patients and controls. There are
several possibilities regarding this
 discrepancy.
First, the in vitro function of the CX26
GJ channels observed in cell lines can be
different from their in vivo function. In
our in vitro assays, the VG* and I*G* type
channels displayed reduced channel ac-
tivities, but did not entirely lose their
function, as shown in previously re-
ported p.D46E mutation (Table 1 and see
Figure 3) (28). Thus, it can be postulated
that the VG* and I*G* types also can
cause mild defects in channel function
in vivo. It has been reported that other
connexins coexpressed with CX26 in the
cochlea, such as Cx30 and Cx31, can
compensate for defective function of
other connexins (27,36,37). Therefore, it is
possible that other connexins may com-
plement the defect in channel  function
caused by the VG* and I*G*  variants.
Second, the VG* type may be associ-
ated with HL, but the I*G* type may rep-
resent a benign polymorphism. In our
functional study, the VG* type displayed
the most serious defect in channel activ-
ity among the four haplotypes, while the
I*G* type led to a milder defect than VG*
Table 2. Allele and genotype frequencies (%) of p.V27I and p.E114G variants in NSHL
patients and normal hearing controls.
Amino NSHL 
Variables acid Controls (%) patients (%) P value Odds ratio (95% CI)]
rs2274084 (p.V27I)
Allele
C V 166 (59.7) 339 (62.1) 0.508 1.105 [0.822~1.484]
T I 112 (40.3) 207 (37.9)
Genotypes
CC VV 55 (39.6) 109 (39.9) 0.501 –
CT VI 56 (40.3) 121 (44.3)
TT II 28 (20.1) 43 (15.8)
rs2274083(p.E114G)
Allele
T E 226 (81.3) 428 (78.4) 0.330 0.835 [0.580~1.201]
C G 52 (18.7) 118 (21.6)
Genotypes
TT EE 96 (69.1) 171 (62.6) 0.331 –
TC EG 34 (24.5) 86 (31.5)
CC GG 9 (6.5) 16 (5.9)
aCI: confidence interval.
Table 3. Haplotype frequencies of p.V27I and p.E114G in NSHL patients and normal
hearing controls.
Haplotypes Controls (%) Patients (%) P value Odds ratio (95% CI)
VE 166 (59.7) 336 (61.5) 0.554 1.093 [0.814~1.470]
I*E 60 (21.6) 92 (16.8) 0.115 0.747 [0.520~1.074]
VG* 0 (0.0) 3 (0.5) – –
I*G* 52 (18.7) 115 (21.1) 0.420 1.162 [0.807~1.675]
aCI: confidence interval.
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type. The I*G* type is detected in both
patients and controls at similar frequen-
cies in Korean population, suggesting
that the I*G* type represents a nonpatho-
genic polymorphism. Although the VG*
type was detected in heterozygous form
(VE/VG*) in three HL patients and not
in normal hearing controls, such differ-
ence was not significant statistically be-
cause of the small number of the patients
carrying this type. Nevertheless, we
think, based on our results, that the VG*
type is associated with HL, which re-
quires future studies. Recently, the VG*
type was detected in both patients and
controls in the Chinese population, but
the frequency of the VG* type was much
higher in patients than that in controls,
which also supports the view that the
VG* type is associated with hearing im-
pairment (38). Moreover, the genetic
study of GJB2 mutation by Dai et al.
(2010) only found two patients with
c.155_c.158delTCTG and VG* and one
patient with c.235delC and VG* out of
2,063 Chinese patients with nonsyn-
dromic hearing impairment. These obser-
vations support the view that the VG*
type is more strongly associated with
hearing loss (39).
The association of the p.V37I and
p.M34T variants with HL has been simi-
larly controversial, because these variants
were detected in both patients and con-
trols (40–42). However, in in vitro func-
tional studies, including electrophysio-
logical analysis in Xenopus oocytes or
biochemical coupling analysis, these vari-
ants showed total loss of function pheno-
type (43–45). Other studies also have
shown that these variants are associated
with a mild-to-severe form of HL when
they exist as homozygotes or compound
heterozygotes with other mutations, such
as c.35delG, c.167delT or c.235delC
(12,46–48). Therefore, as with the results
from our p.V37I and p.M34T studies, we
speculate that the VG* type is associated
with a mild-to-severe form of HL, which
depends on the mutations segregating in
the second allele at this locus.
In summary, our cell-based functional
assays and population studies of the four
haplotypes generated by the p.V27I and
p.E114G variants in GJB2, indicate that
the p.V27I variant may compensate the
defective channel activities when it coex-
ists with p.E114G type. Although our
in vitro experiments of I*G* type showed
a defect in channel activity, the similar
frequencies of I*G* haplotype in patients
and controls suggest that the I*G* variant
is not associated with HL. The data from
Korean (current study) and Chinese pop-
ulations (38) suggest that one copy of the
VG* form with VE type (VE/VG*) may
be nonpathogenic, but the VG* homozy-
gous form (VG*/VG*) or compound het-
erozygote carrying the VG* type with
other mutations may be associated with
HL. To clarify the exact role of the VG*
type in HL, careful follow-up genetic
studies and clinical evaluation are
needed.
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